Related Experiment Video
Updated: Aug 6, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7 for 11: Updates in pediatric atopic dermatitis
1Weill Cornell Medicine, New York, NY.
Summary
Atopic dermatitis (AD) management in children is complex. This review highlights evolving insights into prevention, risk factors, and therapies for pediatric atopic dermatitis to improve long-term care.
Area of Science:
- Pediatric Dermatology
- Immunology
- Public Health
Background:
- Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease in children.
- AD presents multifaceted challenges, evolving from infancy through adolescence.
- Effective management requires comprehensive educational and therapeutic strategies.
Purpose of the Study:
- To review recent advancements in pediatric atopic dermatitis (AD).
- To focus on emerging data for primary prevention and risk factors.
- To guide the long-term management of AD in the pediatric population.
Main Methods:
- Focused review of recently published literature.
- Synthesis of emerging data on pediatric atopic dermatitis.
- Analysis of risk factors, comorbidities, and therapeutic approaches.
Main Results:
- Insights into primary prevention strategies are evolving.
- Understanding of risk factors for AD and allergic comorbidities is advancing.
- New targeted therapies for pediatric AD are emerging.
Conclusions:
- Comprehensive awareness of evolving data is crucial for managing pediatric AD.
- Long-term successful management hinges on updated knowledge of prevention and therapies.
- This review aids clinicians in navigating complex pediatric atopic dermatitis care.
Related Concept Videos
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
02:06Allergic Reactions
Overview
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:29Staphylococcal Skin Infections
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...